BOSTON , Sept. 30, 2022 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Robert Weiskopf , Stealth's chief financial officer, is leaving the company effective September 30, 2022 . Mr. Weiskopf joined Stealth in 2019 following the company's initial public offering to spearhead its public financial reporting activities and grow the Company's financial team.
"On behalf of the entire team and Board of Directors, we thank Rob for his significant contributions to Stealth over the past few years, and wish him the best in his future endeavors," said Reenie McCarthy , Stealth's CEO. "Rob has played a key role in building the infrastructure to support Stealth as a public company and developing its accounting and reporting capabilities. Rob leaves the company with a strong accounting and financial reporting foundation as well as a talented finance and accounting team," Ms. McCarthy said. On August 1, 2022 , the Company announced that it had entered into a definitive agreement to be acquired by a consortium of investors led by Morningside Venture (I) Investments Ltd. for itself and on behalf of its affiliates and J. Wood Capital Advisors LLC in an all-cash going private transaction.
Mr. Weiskopf said, "It has been an honor to serve as CFO of Stealth over the past three years. I have confidence in the Company's finance and management team to guide the Company into its next stage of development. I look forward to seeing the Company continue to progress its strategy to develop novel therapies for patients with high unmet needs due to diseases involving mitochondrial dysfunction."
We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the eye, the neuromuscular system, the heart and the brain. We believe our lead product candidate, elamipretide, has the potential to treat ophthalmic diseases entailing mitochondrial dysfunction, such as dry age-related macular degeneration, rare neuromuscular disorders, such as primary mitochondrial myopathy and Duchenne muscular dystrophy, and rare cardiomyopathies, such as Barth syndrome. We are evaluating our second-generation clinical-stage candidate, SBT-272, for rare neurological disease indications, such as amyotrophic lateral sclerosis and frontotemporal dementia, following promising preclinical data. We have optimized our discovery platform to identify novel mitochondria-targeted compounds which may be nominated as therapeutic product candidates or utilized as mitochondria-targeted vectors to deliver other compounds to mitochondria.
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Stealth BioTherapeutics' expectations for its finance and accounting functions and the ability of the company to achieve its drug discovery, development, and commercialization goals. Statements that are not historical facts, including statements about Stealth BioTherapeutics' beliefs, plans and expectations, are forward-looking statements. The words "anticipate," "expect," "hope," "plan," "potential," "possible," "will," "believe," "estimate," "intend," "may," "predict," "project," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Stealth BioTherapeutics may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements as a result of known and unknown risks, uncertainties and other important factors, including: Stealth BioTherapeutics' ability to obtain additional funding and to continue as a going concern; the impact of the COVID-19 pandemic; the ability to successfully demonstrate the efficacy and safety of Stealth BioTherapeutics' product candidates and future product candidates; the preclinical and clinical results for Stealth BioTherapeutics' product candidates, which may not support further development and marketing approval; the potential advantages of Stealth BioTherapeutics' product candidates; the content and timing of decisions made by the FDA, the EMA or other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, which may affect the initiation, timing and progress of preclinical studies and clinical trials of Stealth BioTherapeutics product candidates; Stealth BioTherapeutics' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials; unplanned cash requirements and expenditures; competitive factors; Stealth BioTherapeutics' ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing; and general economic and market conditions. These and other risks are described in greater detail under the caption "Risk Factors" included in the Stealth BioTherapeutics' most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC"), as well as in any future filings with the SEC. Forward-looking statements represent management's current expectations and are inherently uncertain. Except as required by law, Stealth BioTherapeutics does not undertake any obligation to update forward-looking statements made by us to reflect subsequent events or circumstances.
Investor Relations Kendall Investor Relations Adam Bero , Ph.D. abero@kendallir.com IR@StealthBT.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-departure-of-chief-financial-officer-301638226.html
The Chinese electric vehicle maker NIO (NYSE: NIO) has taken investors on a wild ride since its IPO in Sept. 2018. However, both NIO and Li are still far ahead of their smaller American counterparts like Lucid (NASDAQ: LCID), which expects to produce 6,000 to 7,000 vehicles this year, and Rivian (NASDAQ: RIVN), which is trying to ramp up its production to manufacture 25,000 vehicles this year.
Billionaire hedge-fund investor Paul Tudor Jones says investors looking to time the bottom in stocks should keep a close eye on short-term Treasury yields.
Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Anyone who held Carnival Corporation...
Yahoo Finance's Alexandra Semenova breaks down what to watch from big banks as they're set to release earnings this week.
After the annus horribilis of 2022, with the final quarter now in play, investors will be hoping a late-year rally will materialize. According to Carson Group's chief market strategist Ryan Detrick, that’s not such a far-fetched idea. "While October has a reputation for crashes, it is really a bear market killer,” Detrick recently wrote. “Of the past 17 bear (or near bear markets), stocks bottomed in October six times. Could it happen again? With sentiment this pessimistic and extremely positive
If you're searching for a low-risk, high-yield dividend stock, this wireless leader could be worth considering.
Alibaba Group Holding (NYSE:BABA) has had a rough three months with its share price down 27%. However, the company's...
Shares of enterprise software companies Twilio (NYSE: TWLO), Snowflake (NYSE: SNOW), and Appian (NASDAQ: APPN) fell hard again Monday, down 6.3%, 9.3%, and 6.5%, respectively, as of 3:44 p.m. EDT. In addition, long-term bond yields remained high. On Monday, cloud-based service-center software company Five9 (NASDAQ: FIVN) plunged over 25%, after CEO Rowan Trollope announced he would be resigning for another role at a pre-IPO tech company.
Many hyper-growth stocks skyrocketed to all-time highs last year as overly bullish investors convinced themselves it was reasonable to pay 30, 40, or even 50 times sales for unprofitable tech companies. Let's take a look at three promising hyper-growth stocks that investors should consider buying today before the bulls come back: Snowflake (NYSE: SNOW), CrowdStrike (NASDAQ: CRWD), and Cloudflare (NYSE: NET).
Video game retailer GameStop sells for 59% less than its 52-week high, and meal-kit specialist Blue Apron has fallen back into penny stock territory. The next meme stock with real potential to return to penny-stock status may be AMC Entertainment Holdings (NYSE: AMC). Although a good portion of the audience populating this cinema chain's theaters has returned, the movie theater stock faces an uncertain future as it tries to overcome numerous struggles.
A Cowen analyst says chip stocks are near all-time low valuations after their big drops this year. Several offer solid buying opportunities.
Altria (MO) closed at $43.46 in the latest trading session, marking a +1.49% move from the prior day.
Verizon Communications (VZ) closed at $36.62 in the latest trading session, marking a -0.62% move from the prior day.
It's looking like a rough day for stocks. Our call of the day is a look at the future and a billion-dollar industry and some stocks to play it, from Citigroup.
There's a well-known principle in retirement planning called the 4% rule. One way to supplement income in retirement and make sure that withdrawals don't deplete the nest egg too quickly is to invest in dividend stocks. Dividend stocks generate income without the need to sell assets.
Several oil companies enable investors to immediately cash in on higher oil prices because of their unique capital return strategies. Three of the top oil stocks to buy to cash in on the prospect of higher crude oil prices are ConocoPhillips (NYSE: COP), EOG Resources (NYSE: EOG), and Pioneer Natural Resources (NYSE: PXD). ConocoPhillips launched a unique three-tiered capital return program this year, allowing it to send additional money back to shareholders depending on oil prices.
Shares of the oil company focused on utilizing carbon dioxide have spiked more than 60% from their bottom in late July, fueled by acquisition speculation and higher oil prices. According to a recent Bloomberg report, oil giant ExxonMobil (NYSE: XOM) is among the interested bidders. Here's a look at why Exxon is exploring an acquisition of Denbury.
Yahoo Finance Live anchors discuss stock performance for PayPal as well as why the financial tech company is backtracking on its misinformation policy.
In this article, we discuss 10 best hydrogen and fuel cell stocks to buy in 2022. If you want to read about some more hydrogen and fuel cell stocks, go directly to 5 Best Hydrogen and Fuel Cell Stocks to Buy in 2022. The hydrogen and fuel cell market has come under increased media spotlight […]
It's inevitable that offspring are compared with their parents. This happens with famous people and not-so-famous people alike. And it also happens with companies. For example, Abbott Laboratories (NYSE: ABT) spun off AbbVie (NYSE: ABBV) in 2013.